clinical trial · NCT00758342
Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
Alcon Research·phase4·terminated·n = 37
Intraocular PressureTravoprost 0.004% + Brinzolamide 1.0%Travoprost 0.004% + Tears Natural
brief summary
To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily. The study is double masked. The patients will receive either treatment for 12 weeks.
started
May 1, 2006
primary completion
Mar 1, 2008
completion
Mar 1, 2008
last updated
Dec 5, 2023
official title
A Double-Masked, Parallel-Group, Efficacy and Safety Study of Brinzolamide 1.0% (AZOPT) as Adjunctive Therapy to Travoprost 0.004% (TRAVATAN) in Patients With Chronic Angle-Closure Glaucoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol